Drug intelligence / Profile preview

AZD5156

Development stage: Phase 3
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular, Intravenous

Overview

**AZD5156** is AstraZeneca's investigational fixed-dose combination of two long-acting anti-SARS-CoV-2 monoclonal antibodies: sipavibart and cilgavimab. Both antibodies bind distinct epitopes in the receptor-binding domain of the SARS-CoV-2 spike glycoprotein, neutralizing viral entry by blocking spike interaction with the host ACE2 receptor. It was evaluated as an intramuscular pre-exposure prophylaxis for COVID-19 in people with immune impairment in the Phase I sentinel component of the SUPERNOVA program. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/10/NCT05648110/Prot_004.pdf))

Other names: AZD1061 + AZD3152AZD3152 + AZD1061cilgavimab + sipavibartsipavibart + cilgavimab

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on AZD5156.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD5156.

Explore the full profile